Latest Market Data
Refresh
Market Turnover
-






-
-
|
|
|
|
|
|
-
-
-
Loading

3D MEDICINES INC. (1244)

3D MEDICINES (1244)

HK$5.800

+0.200 (+3.57%)

Prev. Close is the most recent non-zero closing value or settlement price.PREV. CLOSE
HK$5.600
Open price is the first traded price of the day. The opening price is reported after 09:20:00 HKT.OPEN
HK$5.510
TURNOVER
HK$5.69M
VOLUME
1.04M
MKT CAP
HK$1.49B
LOT SIZE
500
BID
HK$5.740
ASK
HK$5.800
EPS
-
P/E
-
DIV YIELD
-
INTRA-DAY 52W
High HK$5.800 HK$6.180
Low HK$5.350 HK$1.600
Information is available after the market opens and is delayed by at least 15 minutes.
Updated: 23 Jul 2025 16:08 HKT
  • 1 D
  • 1 M
  • 3 M
  • 6 M
  • YTD
  • 1 Y
  • 2 Y
  • 5 Y
  • 10 Y
1min
5min
15min
Hourly
Created with Highstock 6.2.00.0005.0405.2805.5205.7606.0000200K400K10:0011:0012:0013:0014:0015:0016:00Prev. Close
5.600
All charts use the last traded price or closing price.

COMPANY PROFILE

3D Medicines Inc is a holding company mainly engaged in the research and development (R&D) and commercialization of biopharmaceuticals. The Company focuses on the discovery, development and commercialization of innovative drugs in the field of cancer chronic disease treatment, and also lays out the field of cancer pain management. The Company has built a complete set of internal R&D systems, and has covered the entire process from drug discovery, preclinical development, clinical trials, and registration. The Company's first marketed drug, Envafolimab, is a subcutaneously injected PD-L1 inhibitor for the treatment of pan-tumor types. The Company also has a number of innovative drug research and development pipelines. The Company primarily operates in the domestic Chinese market. *
Please click to see notes of Issued Shares.Issued Shares (excluding treasury shares) 258,177,000 (as at 30 Jun 2025)
Industry Healthcare - Pharmaceuticals & Biotechnology - Biotechnology Industry Classification (HSIC) is provided by Hang Seng Indexes Company Limited. Please see the . (HSIC)
Listing Date 15 Dec 2022
Financial Year Ends 31 Dec 2024
Chairman Gong Zhaolong
Principal Office 19th Floor
Golden Centre
188 Des Voeux Road Central
Hong Kong
Place of Incorporation Cayman Islands
Listing Category Primary Listing

a. Updating time-lag
The number of issued shares / issued units presented is generally updated within 7 days after the Monthly Returns and Next Day Disclosure Returns published by the listed issuers on the HKEXnews website. Hence, the information presented here may not be the most up-to-date information submitted by the listed issuers as required under the Listing Rules.
b. Rights issues or bonus issues
The number of issued shares / issued units presented here will be adjusted with effect from the ex-date in the event of announced rights issues or announced bonus issues. In this case, both the number of issued shares / issued units before and after the adjustment will be presented.
c. Share splits or share consolidations
The number of issued shares / issued units presented here will be adjusted on the effective date in the event of share splits or share consolidations.
d. Conversion of convertible notes into shares
If the change of the number of issued shares / issued units is due to conversion of convertible bonds, the number of issued shares / issued units presented here may be updated based on the related company announcement.
Updated: 23 Jul 2025 18:39 HKT
* Company profile is provided by Refinitiv.

ENTITLEMENT

Date Announced Ex-Date Details Financial Year End Book Close Date Payment date may be indicative only.Payment Date
31 Mar 2025-No Dividend for the period ended
2024/12/31
31 Dec 2024--
30 Aug 2024-No Dividend for the period ended
2024/06/30
31 Dec 2024--
28 Mar 2024-No Dividend for the period ended
2023/12/31
31 Dec 2023--
25 Aug 2023-No Dividend for the period ended
2023/06/30
31 Dec 2023--
30 Mar 2023-No Dividend for the period ended
2022/12/31
31 Dec 2022--
Updated: 23 Jul 2025 01:15 HKT
Dividend details are sourced from Announcement Forms published on HKEXnews